If you’re looking for the perfect holiday dish, look no further than this rich and tasty cake that’s relatively easy to make.

After hours: November 29 at 4:59 PM EST Loading Chart for SAVA ...

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...

AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences SAVA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024.

Cassava Sciences ( (SAVA)) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cassava Sciences, Inc., a clinical-stage biotechnology ...